Published ·
FDA letter on DSHEA disclaimer placement
The FDA’s industry letter describes enforcement discretion over repeating the disclaimer on every panel with an applicable claim.

What the letter addresses
In its December 11, 2025 letter, the FDA said it was considering amendments to the placement rules in 21 CFR 101.93(d). While reviewing the rules, it intends to exercise enforcement discretion on the provision requiring the disclaimer to appear on each label panel that carries an applicable claim.
How the disclaimer relates to claims
The letter addresses repeated placement across panels. The requirement to include the disclaimer on the label and connect it to each applicable claim remains in place under the policy described in the letter. Applicable claims include structure/function statements. The letter describes placement next to the claim or a symbol, such as an asterisk, that links the claim to the disclaimer.

